Table 1.
Main demographic, clinical characteristics, and follow-up of the study population (n=926)
| Cohort Characteristics | Total (n=926) |
|---|---|
| Data at time of transplantation | |
| Recipient demographics | |
| Female, n (%) | 372 (40.2) |
| Age (yr), mean±SD | 53.8±13.2 |
| Repeat transplantation, n (%) | 132 (14.3) |
| Weight (kg), mean±SD | 72.8±14.8 |
| Body mass index (kg/m2), mean±SD | 25.4±4.51 |
| White race, n (%) | 911 (98.4) |
| Pretransplant diabetes mellitus, n (%) | 163 (17.6) |
| Donor demographics | |
| Female, n (%) | 431 (46.5) |
| Age (yr), mean±SD | 47.9±14.9 |
| Living donor, n (%) | 42 (4.54) |
| Donation after brain death, n (%) | 732 (79.1) |
| Donation after cardiac death, n (%) | 152 (16.4) |
| Cold ischemia time (h), mean±SD | 14.4±5.50 |
| Transplant characteristics | |
| HLA-A/B/DR antigen mismatches (0–6), mean±SD | 2.70±1.30 |
| HLA-A/B/DR/DQ antigen mismatches (0–8), mean±SD | 3.40±1.61 |
| A antigen, mean±SD | 0.97±0.70 |
| B antigen, mean±SD | 1.02±0.64 |
| DR antigen, mean±SD | 0.71±0.56 |
| DQ antigen, mean±SD | 0.70±0.61 |
| Total eplet mismatch load, mean±SD | 36.7±18.0 |
| Antibody-verified eplet mismatch load, mean±SD | 16.0±8.7 |
| Pretransplant HLA antibodies, n (%) | 225 (24.3) |
| HLA class 1, n (%) | 76/225 (33.8) |
| HLA class 2, n (%) | 52/225 (23.1) |
| HLA class 1 and 2, n (%) | 97/225 (43.1) |
| Pretransplant DSAs, n (%) | 94 (10.2) |
| HLA class 1, n (%) | 33/94 (35.1) |
| HLA class 2, n (%) | 40/94 (42.6) |
| HLA class 1 and 2, n (%) | 21/94 (22.3) |
| Immunosuppression regimen of TAC-MPA-CS, n (%) | 808 (87.3) |
| Induction therapy, n (%) | 383 (41.4) |
| Basiliximab, n (%) | 331 (35.8) |
| Thymoglobulin, n (%) | 19 (2.1) |
| Other, n (%) | 33 (3.6) |
| Post-transplant data | |
| Overall graft survival, %a | |
| At 1 yr | 93.8 |
| At 2 yr | 91.1 |
| At 5 yr | 81.0 |
| Death-censored graft survival, %b | |
| At 1 yr | 95.6 |
| At 2 yr | 94.5 |
| At 5 yr | 89.0 |
| dnDSAs, n (%) | 43 (4.64) |
| HLA class 1, n (%) | 9/43 (20.9) |
| HLA class 2, n (%) | 32/43 (74.4) |
| HLA class 1 and 2, n (%) | 2/43 (4.7) |
TAC, tacrolimus; MPA, mycophenolic acid; CS, corticosteroids.
a
Overall graft survival: composite of graft failure and recipient death.
b
Death-censored graft survival: graft failure censored at time of recipient death with a functioning graft.